FUT1 and leukemia: Of note, while current clinical trials targeting minor H antigens are evaluating the safety profile of minor H antigen-specific T cells as treatment for post-HCT leukemia recurrence, a longer-term goal is to deliver hematopoietic-restricted minor H antigen-specific T cells soon after the HCT graft to augment GVL and prevent relapse.